Mutations in two gene pairs point to a promising drug target in 5% of adult cancers

Scientists from the Cancer Dependency Map (DepMap) at the Broad Institute of MIT and Harvard and Columbia University have discovered that about 5% of adult cancers rely heavily on a gene called PELO to survive and that disabling the gene kills those cancer cells. These cancers have mutations in one of two genes, FOCAD or TCC37.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup